Skip to main content
CDNA
NASDAQ Industrial Applications And Services

CareDx 10-Q Details $250M Cash, Naveris Deal Accounting and New Insider Selling Plans

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Diagnostics & Research Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$78
Mkt Cap
$3.7B
52W Low
$14.225
52W High
$73.43
52W Position info
448% above low
Off High info
at 52W high
Rel. Volume info
1.2× avg
Market data snapshot near publication time

CDNA has more than doubled off its 52-week low of $14.225.

Summary

CareDx's Q3 10-Q backs up the same-day earnings release with $250.5 million of cash, no debt, and full Naveris deal accounting, while disclosing new 10b5-1 selling plans from the CEO, CFO and four other insiders.


Key Events · Earnings and Guidance · CDNA

  • Q3 Revenue Up 39% to $139.4M

    Total revenue was $139.4 million versus $100.1 million a year ago, with testing services up 65% to $119.2 million and patient and digital solutions up 31% to $20.2 million.

  • Prior-Period Catch-Up Inflates Growth

    Q3 included $17.3 million of revenue for tests performed in prior periods (versus $5.9 million a year ago), partly offset by a $2.6 million refund reserve increase; excluding NavDx, testing volume grew 20.8%.

  • Balance Sheet: $250.5M Cash, No Debt

    Cash and cash equivalents were $250.5 million at September 30, 2026, up from $65.4 million at year-end after the $164.8 million net lab-products sale proceeds and $145.8 million Naveris cash outlay.

  • Naveris Deal: $203.3M Plus $100M Earnout

    Consideration was $151.7 million cash to sellers plus $44.0 million of contingent consideration fair value, creating $125.1 million of intangibles and $85.7 million of goodwill; equity holders can earn up to $100.0 million more on 2026-2027 revenue milestones.


Analysis · CDNA · Industrial Applications And Services

The headline numbers were already out via the same-day 8-K, but the 10-Q fills in what that release did not: $250.5 million of cash and no debt, the full Naveris purchase accounting ($203.3 million consideration, $85.7 million of goodwill, up to $100 million of revenue-milestone earnout), and a cluster of new 10b5-1 selling plans adopted in August by the CEO, CFO, CCO, general counsel and two directors. The quarter itself was strong — revenue of $139.4 million, up 39%, with net income of $19.3 million — though $17.3 million of that revenue came from tests performed in prior periods, so the underlying growth rate is lower than the headline. The earnout is the item to track: it is tied to NavDx revenue in 2026 and 2027, and a miss would cut what CareDx ultimately pays but also signal the oncology bet is underperforming.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CDNA was trading at $78.00 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $3.7B. The 52-week trading range was $14.23 to $73.43. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CDNA - Latest Insights

CDNA
Oct 29, 2026, 4:02 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $80.04
Real-time Price: $79.67 info
Change: -$0.370 (-0.46%) info
Market Cap: $4.186B info
CDNA
Oct 29, 2026, 4:01 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $71.49
Real-time Price: $79.67 info
Change: +$8.18 (+11%) info
Market Cap: $4.186B info
CDNA
Sep 16, 2026, 4:06 PM EDT
Filing Type: 8-K/A
Importance Score:
8
Price at Filing: $53.55
Real-time Price: $79.67 info
Change: +$26.12 (+49%) info
Market Cap: $4.186B info
CDNA
Aug 03, 2026, 7:33 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $44.99
Real-time Price: $79.67 info
Change: +$34.68 (+77%) info
Market Cap: $4.186B info
CDNA
Aug 01, 2026, 3:14 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $42.99
Real-time Price: $79.67 info
Change: +$36.68 (+85%) info
Market Cap: $4.186B info